Full text is available at the source.
Safety and efficacy of glucagon‐like peptide‐1 (GLP‐1) receptor agonists in patients with weight regain or insufficient weight loss after metabolic bariatric surgery: A systematic review and meta‐analysis
Safety and effectiveness of GLP-1 drugs for patients who regain weight or don’t lose enough after weight-loss surgery
AI simplified
Abstract
The mean weight loss observed was 7.02 kg after treatment with GLP-1 receptor agonists for ≤ 6 months.
- Liraglutide and semaglutide were administered at maximum doses of 3 mg per day and 1 mg once weekly, respectively.
- Weight loss and body mass index reductions were noted at different treatment durations, with the greatest loss occurring in the first 6 months.
- Weekly semaglutide resulted in a mean weight loss that was 4.15 kg greater than that achieved with daily liraglutide.
- Common side effects included nausea (19.1%), constipation (8.6%), abdominal pain (3.7%), and vomiting (2.4%).
- GLP-1 receptor agonists are associated with effective management of weight regain and insufficient weight loss after metabolic bariatric surgery.
AI simplified